The FDA has torn into Exeltis over a social media sponsored post for birth control pill Slynd, lambasting the drugmaker for leaving out all the risk information, making misleading efficacy claims and failing to submit the material at the time of initial publication.
A sponsored social media post for Slynd birth control is the latest ad offender in the eyes of the FDA’s promotions watchdog. The Office of Prescription Drug Promotion (OPDP) sent an untitled letter to Exeltis over “false and misleading” claims in a social media post for its progestin-only birth control pill.
BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients. SOLOSEC® is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).